v3.26.1
Segment Data (Details)
 3 Months Ended 6 Months Ended
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
Segment
Jun. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
Segment Information          
Number of reportable segments | Segment     2    
Right-of-use asset $ 1,011,000   $ 1,011,000   $ 1,000,000
External revenue 1,225,000 $ 2,979,000 21,497,000 $ 5,193,000  
Cost of product revenue 1,031,000 527,000 2,189,000 1,042,000  
Research and development 3,336,000 3,265,000 7,264,000 6,995,000  
Sales and marketing 5,000 2,467,000 901,000 4,960,000  
General and administrative 4,450,000 4,727,000 8,558,000 9,624,000  
Interest 161,000 (15,000) 860,000 (71,000)  
Net comprehensive income (loss) (12,801,000) (10,582,000) (4,536,000) (21,441,000)  
Segment net loss (12,802,000) (10,560,000) (4,079,000) (21,156,000)  
Segment assets 34,194,000   34,194,000   38,323,000
Napo Therapeutics Lease Office | Europe          
Segment Information          
Right-of-use asset 117,000   117,000   87,000
Property, Plant, and Equipment, Right-of-Use Assets, and Intangible Assets | US          
Segment Information          
Right-of-use asset 16,400,000   16,400,000   17,400,000
Product revenue, net          
Segment Information          
External revenue 1,182,000 2,936,000 2,386,000 5,107,000  
Operating Segments          
Segment Information          
External revenue 1,225,000 2,979,000 21,497,000 5,193,000  
Cost of product revenue 1,031,000 527,000 2,189,000 1,042,000  
Research and development 3,331,000 3,269,000 7,255,000 6,995,000  
Sales and marketing 5,000 2,467,000 901,000 4,960,000  
General and administrative 4,965,000 5,242,000 9,578,000 10,582,000  
Interest 161,000 (15,000) 860,000 (71,000)  
Other segment items 5,335,000 2,755,000 6,719,000 4,241,000  
Segment expenses 14,828,000 14,245,000 27,502,000 27,749,000  
Net comprehensive income (loss) (13,603,000) (11,266,000) (6,005,000) (22,556,000)  
Segment assets 201,136,000   201,136,000   213,832,000
Operating Segments | Human Health          
Segment Information          
External revenue 1,175,000 2,863,000 21,102,000 5,001,000  
Cost of product revenue 960,000 517,000 1,947,000 1,023,000  
Research and development 2,836,000 2,600,000 6,005,000 5,714,000  
Sales and marketing (45,000) 2,301,000 658,000 4,697,000  
General and administrative 1,943,000 2,000,000 3,914,000 4,003,000  
Interest 159,000   346,000 1,000  
Other segment items (57,000) 155,000 986,000 465,000  
Segment expenses 5,796,000 7,573,000 13,856,000 15,903,000  
Net comprehensive income (loss) (4,621,000) (4,710,000) 7,246,000 (10,902,000)  
Segment assets 27,439,000   27,439,000   28,321,000
Operating Segments | Animal Health          
Segment Information          
External revenue 50,000 116,000 395,000 192,000  
Cost of product revenue 71,000 10,000 242,000 19,000  
Research and development 495,000 669,000 1,250,000 1,281,000  
Sales and marketing 50,000 166,000 243,000 263,000  
General and administrative 3,022,000 3,242,000 5,664,000 6,579,000  
Interest 2,000 (15,000) 514,000 (72,000)  
Other segment items 5,392,000 2,600,000 5,733,000 3,776,000  
Segment expenses 9,032,000 6,672,000 13,646,000 11,846,000  
Net comprehensive income (loss) (8,982,000) (6,556,000) (13,251,000) (11,654,000)  
Segment assets 173,697,000   173,697,000   185,511,000
Eliminations And Reconciling Items [Member]          
Segment Information          
Net comprehensive income (loss) 802,000 $ 684,000 1,469,000 $ 1,115,000  
Segment Reconciling Items          
Segment Information          
Segment assets (29,231,000)   (29,231,000)   (29,231,000)
Intersegment Eliminations          
Segment Information          
Segment assets $ (137,711,000)   $ (137,711,000)   $ (146,278,000)